Future oncology (London, England) · 2017
A review of bevacizumab in the treatment of malignant pleural mesothelioma.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brosseau Solenn, Assoun Sandra, Naltet Charles, Steinmetz Christelle, Gounant Valérie, Zalcman Gérard
Аннотация
Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.
Предметные рубрики MeSH
Angiogenesis InhibitorsAnimalsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBevacizumabClinical Trials as TopicDrug Evaluation, PreclinicalHumansLung NeoplasmsMesotheliomaMesothelioma, MalignantMolecular Targeted TherapyPleural NeoplasmsRandomized Controlled Trials as TopicTreatment Outcome